Tegafur-uracil

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

WikiDoc Resources for Tegafur-uracil

Articles

Most recent articles on Tegafur-uracil

Most cited articles on Tegafur-uracil

Review articles on Tegafur-uracil

Articles on Tegafur-uracil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tegafur-uracil

Images of Tegafur-uracil

Photos of Tegafur-uracil

Podcasts & MP3s on Tegafur-uracil

Videos on Tegafur-uracil

Evidence Based Medicine

Cochrane Collaboration on Tegafur-uracil

Bandolier on Tegafur-uracil

TRIP on Tegafur-uracil

Clinical Trials

Ongoing Trials on Tegafur-uracil at Clinical Trials.gov

Trial results on Tegafur-uracil

Clinical Trials on Tegafur-uracil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tegafur-uracil

NICE Guidance on Tegafur-uracil

NHS PRODIGY Guidance

FDA on Tegafur-uracil

CDC on Tegafur-uracil

Books

Books on Tegafur-uracil

News

Tegafur-uracil in the news

Be alerted to news on Tegafur-uracil

News trends on Tegafur-uracil

Commentary

Blogs on Tegafur-uracil

Definitions

Definitions of Tegafur-uracil

Patient Resources / Community

Patient resources on Tegafur-uracil

Discussion groups on Tegafur-uracil

Patient Handouts on Tegafur-uracil

Directions to Hospitals Treating Tegafur-uracil

Risk calculators and risk factors for Tegafur-uracil

Healthcare Provider Resources

Symptoms of Tegafur-uracil

Causes & Risk Factors for Tegafur-uracil

Diagnostic studies for Tegafur-uracil

Treatment of Tegafur-uracil

Continuing Medical Education (CME)

CME Programs on Tegafur-uracil

International

Tegafur-uracil en Espanol

Tegafur-uracil en Francais

Business

Tegafur-uracil in the Marketplace

Patents on Tegafur-uracil

Experimental / Informatics

List of terms related to Tegafur-uracil


Overview

Tegafur-uracil is a chemotherapy drug used in the treatment of cancer, primarily bowel cancer. It is also called UFT or UFUR.[1]

UFT is the first generation of DIF(DPD Inhibitory Flouropyrimidine)drug. UFT is an oral agent with combines uracil, a competitive inhibitor of DPD, with the 5-FU prodrug tegafur in a 4:1 molar ratio. Excess uracil competes with 5-FU for DPD, thus inhibiting 5-FU catabolism.

References

Template:WH Template:WikiDoc Sources